New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Scribe Therapeutics Inc.

SCTX

Healthcare Biotechnology

Scribe Therapeutics Inc.’s revenue for fiscal 2025 (year ended December 2025) was $51.2 million.

12.07 1.15 −8.70%

After hours trading: 12.00, down 0.58%, last trade Fri 7:39pm Eastern.

Market cap
$250.4M
P/E
n/m
Fwd P/E FY26e
n/m
Dividend yield
—
F-score
n/a
ROIC
—
Net debt / EBITDA
—
Payout ratio
—

Scribe Therapeutics Inc. (SCTX) news

Stories the last two months, newest first

  1. Product ·

    Scribe reports preclinical data on STX-1150 and STX-1200

    Scribe Therapeutics reported preclinical cardiovascular data at AHA 2026. A single STX-1150 prototype dose lowered LDL-C by more than 50% for two years in non-human primates, and repeat dosing further reduced LDL-C while remaining tolerable. STX-1200 surrogate treatment reduced Lp(a) by more than 95% in non-human primates, with no detectable off-target editing across nominated sites in human liver cells.

    Reported by Globe Newswire

  2. Deal ·

    Sanofi expands Scribe Therapeutics collaboration to include ELXR platform

    Sanofi expanded its collaboration with Scribe Therapeutics to access Scribe’s ELXR epigenetic silencing platform for early-stage research. The deal broadens Sanofi’s gene-editing toolkit, while a separate milestone payment to Novavax supports a Phase III flu and COVID-19 combination vaccine trial. The moves fit Sanofi’s effort to build its pipeline through partnerships, though their ability to offset terminated programs and margin pressure remains uncertain.

    Reported by Simply Wall St.

  3. Results ·

    Scribe Therapeutics reports third-quarter net loss of $9.9 million

    Scribe Therapeutics reported $174.2 million in cash and marketable securities at quarter-end, with runway into the first half of 2029 after its $155.5 million IPO and private placement. Enrollment continues in the Phase 1 trial of STX-1150, with initial clinical data expected in the first half of 2027. Third-quarter net loss was $9.9 million.

    Reported by GlobeNewswire

  4. Other ·

    Scribe to present cardiovascular program data at AHA sessions

    Scribe Therapeutics will present preclinical data on two cardiovascular programs at the 2026 AHA Scientific Sessions. The company says a single dose of its PCSK9-targeting epigenetic silencing therapy STX-1150 maintained LDL-C control for at least two years in non-human primates; the therapy is in a Phase 1 trial. A second presentation will cover preclinical results for STX-1200, a CRISPR gene editor designed to reduce Lp(a).

    Reported by GlobeNewswire

More headlines